Difference between revisions of "Plasma cell leukemia"
Jump to navigation
Jump to search
m |
|||
| Line 11: | Line 11: | ||
=First-line therapy= | =First-line therapy= | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==PAD/VCD {{#subobject:cc293b|Regimen=1}}== | ==PAD/VCD {{#subobject:cc293b|Regimen=1}}== | ||
| Line 46: | Line 17: | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
| − | PAD: '''<u>P</u>'''S-341 (Bortezomib), '''<u>A</u>'''driamycin liposomal (Doxorubicin liposomal), '''<u>D</u>'''examethasone | + | PAD/VCD: '''<u>P</u>'''S-341 (Bortezomib), '''<u>A</u>'''driamycin liposomal (Doxorubicin liposomal), '''<u>D</u>'''examethasone alternating with '''<u>V</u>'''elcade (Bortezomib), '''<u>C</u>'''yclophosphamide, '''<u>D</u>'''examethasone |
| − | |||
===Regimen {{#subobject:9763fb|Variant=1}}=== | ===Regimen {{#subobject:9763fb|Variant=1}}=== | ||
| Line 58: | Line 28: | ||
|- | |- | ||
|} | |} | ||
| − | ====PAD portion==== | + | ====Chemotherapy, PAD portion==== |
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11 | ||
*[[Pegylated liposomal doxorubicin (Doxil)]] 30 mg/m<sup>2</sup> IV once on day 4 | *[[Pegylated liposomal doxorubicin (Doxil)]] 30 mg/m<sup>2</sup> IV once on day 4 | ||
| Line 65: | Line 35: | ||
'''Two 21-day cycles (1 & 3), alternating with VCD''' | '''Two 21-day cycles (1 & 3), alternating with VCD''' | ||
| − | ====VCD portion==== | + | ====Chemotherapy, VCD portion==== |
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11 | *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11 | ||
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> PO once per day on days 1 & 8 | *[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> PO once per day on days 1 & 8 | ||
| Line 77: | Line 47: | ||
<!-- Presented at the 55th American Society of Hematology Annual Meeting, New Orleans, LA, December 7-10, 2013, and the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milan, Italy, March 30 to April 2, 2014. --> | <!-- Presented at the 55th American Society of Hematology Annual Meeting, New Orleans, LA, December 7-10, 2013, and the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milan, Italy, March 30 to April 2, 2014. --> | ||
# Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. [http://jco.ascopubs.org/content/34/18/2125.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27114594 PubMed] | # Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. [http://jco.ascopubs.org/content/34/18/2125.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27114594 PubMed] | ||
| + | |||
| + | ==Rd {{#subobject:dc6eae|Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | Rd: '''<u>R</u>'''evlimid (Lenalidomide) & low-dose '''<u>d</u>'''examethasone | ||
| + | <br>RevDex: '''<u>Rev</u>'''limid (Lenalidomide) & '''<u>Dex</u>'''amethasone | ||
| + | <br>Ld: '''<u>L</u>'''enalidomide & low-dose '''<u>d</u>'''examethasone | ||
| + | <br>Len-Dex: '''<u>L</u>'''enalidomide & '''<u>D</u>'''examethasone | ||
| + | ===Regimen {{#subobject:be34d7|Variant=1}}=== | ||
| + | {| border="1" style="text-align:center;" !align="left" | ||
| + | |'''Study''' | ||
| + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
| + | |- | ||
| + | |[http://www.nature.com/leu/journal/v28/n1/full/leu2013241a.html Musto et al. 2013] | ||
| + | |style="background-color:#EEEE00"|Phase II | ||
| + | |- | ||
| + | |} | ||
| + | ====Chemotherapy==== | ||
| + | *[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21 | ||
| + | *[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22 | ||
| + | |||
| + | '''28-day cycle for 4 cycles''' | ||
| + | |||
| + | ''Responding patients eligible for transplant proceeded to SCT per center protocol. Responding patients ineligible for transplant received 4 more cycles of Rd, followed by [[#Lenalidomide_monotherapy|lenalidomide maintenance]].'' | ||
| + | |||
| + | ===References=== | ||
| + | # Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014 Jan;28(1):222-5. Epub 2013 Aug 20. [http://www.nature.com/leu/journal/v28/n1/full/leu2013241a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23958922 PubMed] | ||
=Consolidation after first-line therapy= | =Consolidation after first-line therapy= | ||
Revision as of 02:35, 19 November 2017
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
4 regimens on this page
4 variants on this page
|
First-line therapy
PAD/VCD
| back to top |
PAD/VCD: PS-341 (Bortezomib), Adriamycin liposomal (Doxorubicin liposomal), Dexamethasone alternating with Velcade (Bortezomib), Cyclophosphamide, Dexamethasone
Regimen
| Study | Evidence |
| Royer et al. 2016 | Phase II |
Chemotherapy, PAD portion
- Bortezomib (Velcade) 1.3 mg/m2 SC once per day on days 1, 4, 8, 11
- Pegylated liposomal doxorubicin (Doxil) 30 mg/m2 IV once on day 4
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 4, 8, 11
Two 21-day cycles (1 & 3), alternating with VCD
Chemotherapy, VCD portion
- Bortezomib (Velcade) 1.3 mg/m2 SC once per day on days 1, 4, 8, 11
- Cyclophosphamide (Cytoxan) 300 mg/m2 PO once per day on days 1 & 8
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 4, 8, 11
Two 21-day cycles (2 & 4), alternating with PAD
Responding patients proceeded to undergo high-dose melphalan & autologous stem cell transplant.
References
- Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. link to original article contains verified protocol PubMed
Rd
| back to top |
Rd: Revlimid (Lenalidomide) & low-dose dexamethasone
RevDex: Revlimid (Lenalidomide) & Dexamethasone
Ld: Lenalidomide & low-dose dexamethasone
Len-Dex: Lenalidomide & Dexamethasone
Regimen
| Study | Evidence |
| Musto et al. 2013 | Phase II |
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
28-day cycle for 4 cycles
Responding patients eligible for transplant proceeded to SCT per center protocol. Responding patients ineligible for transplant received 4 more cycles of Rd, followed by lenalidomide maintenance.
References
- Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014 Jan;28(1):222-5. Epub 2013 Aug 20. link to original article contains verified protocol PubMed
Consolidation after first-line therapy
Melphalan, then autologous stem cell transplant
| back to top |
Regimen
| Study | Evidence |
| Royer et al. 2016 | Phase II |
Preceding treatment
Chemotherapy
- Melphalan (Alkeran) 200 mg/m2 IV once
- Patients older than 65 years or with CrCl less than 30 mL/min/1.73m2: 140 mg/m2
References
- Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. link to original article contains protocol PubMed
Maintenance after first-line therapy
Lenalidomide monotherapy
| back to top |
Regimen
| Study | Evidence |
| Musto et al. 2013 | Phase II |
Preceding treatment
- Rd x 8
Chemotherapy
- Lenalidomide (Revlimid) 10 mg PO once per day on days 1 to 21
28-day cycles until progression
References
- Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014 Jan;28(1):222-5. Epub 2013 Aug 20. link to original article contains verified protocol PubMed